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We report protease-resistant prion protein (PrPres) in
spontaneous lymphoreticular tumors of mice infected with
the agent of variant Creutzfeldt-Jakob disease (vCJD).
PrPres may accumulate in lymphoreticular system tumors of
asymptomatic persons with vCJD. The statistical power of
estimates of vCJD prevalence might be increased by
expanding screening to include samples of lymphoreticular
neoplasms. 
V
ariant Creutzfeldt-Jakob disease (vCJD) is thought to
be caused by exposure to bovine products contami-
nated with the bovine spongiform encephalopathy agent.
The prevalence of preclinical and subclinical vCJD in the
United Kingdom and other European countries is still
unknown. To date, all tested vCJD patients have shown an
accumulation of misfolded protease-resistant protein
(PrPres), a highly reliable indicator of infection, in lym-
phoreticular tissues such as spleen, tonsil, lymph nodes,
and appendix (1). Although the time PrPres starts to appear
in lymphoreticular tissues of infected persons is unclear, it
has been found in appendixes of 2 persons 8 months and 2
years before vCJD developed (2), in a lymph node and the
spleen of a patient who died from a nonneurologic disor-
der 5 years after receiving a blood transfusion from a
donor in whom vCJD subsequently developed (3), and in
the appendixes of 3 persons from a large retrospective pop-
ulation study (4).
Lymphoreticular accumulation of infectivity and PrPres
occur early after scrapie infection in sheep and in various
experimental animal models of transmissible spongiform
encephalopathies, including mice infected with the vCJD
agent (5). The presence of infectivity and PrPres in
inflamed liver, pancreas, and kidney tissues has been
recently observed in transgenic and spontaneous mouse
models of chronic inflammation on infection with the
Rocky Mountain Laboratory strain of scrapie (6), and
PrPres has been shown in mammary glands of scrapie-
infected sheep with mastitis (7). We report the first obser-
vation of PrPres in spontaneous lymphoreticular tumors of
mice with vCJD. 
The Study
Experimental studies in mice were approved by the
institutional animal care and use committee of the
American Red Cross Holland Laboratory. Ten inbred, 7-
week-old SJL/OlaHsd (Harlan, Bicester, UK) female mice
closely related to the SJL/J strain, which develops sponta-
neous B-cell lymphomas at >8 months of age (8,9), were
intracerebrally injected under isoflurane anesthesia with
1% vCJD human brain homogenate (World Health
Organization reference material) (10) diluted in physiolog-
ic saline, while 4 control animals received physiologic
saline only. Approximately 6 months after infection, visi-
ble tumors developed in the neck areas of 5 mice, 4 with
vCJD and 1 control. Two of the vCJD animals were euth-
anized on day 199 because of rapid tumor growth (Table).
The remaining mice in the vCJD group, including 2 other
animals with tumors, were later euthanized or died (range
222–386 days) without noticeable signs of neurologic
disease.
In the control group, the animal with tumors was euth-
anized on day 321, and the 3 other animals without tumors
were euthanized on day 405. The autopsy of all mice,
infected or not, revealed hepatomegaly and splenomegaly,
with various degrees of white, nodular infiltrations of the
spleen. Mice with visible tumors also had massive neo-
plastic nodular involvement of intestinal, mesenteric, cer-
vical, and axillary lymph nodes and thymus. Brains and
spleens were removed from all mice, and neoplastic tissues
involving lymph nodes were removed from 4 infected and
1 uninfected mouse, and the thymus was removed from 2
infected mice (Table). Organs were sectioned, immediate-
ly frozen on dry ice, and stored at –80°C. PrPres was
extracted from brains by using high-speed centrifugation,
from spleens by using methanol precipitation according to
previously described methods (5), and from tumors with
the procedure applied to the brain. Western blotting (WB)
was performed by using PrPres-specific monoclonal anti-
body 6H4 (Prionics, Schlieren, Switzerland) or 6D11 as
previously described (5).
In the vCJD group, PrPres was identified in the brains
and spleens of all 10 mice. In 4 mice with tumors, PrPres
was found in neoplastic tissues of lymph nodes and also in
the neoplastic thymus of 2 of the mice (Table). The Figure
shows WB analysis of PrPres extracted from the brain of a
vCJD patient and representative tissues of a vCJD mouse
with tumors. The glycosylation pattern of PrPres in mouse
tissues was typical of vCJD; diglycosylated isoforms pre-
dominated over monoglycosylated and unglycosylated
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*American Red Cross, Rockville, Maryland, USAisoforms, with the unglycosylated isoform corresponding
to a 19-kDa fragment. On the basis of WB band intensity,
we observed that the concentration of PrPres in neoplastic
lymphoreticular tissues (lanes 3–5) was similar to that seen
in the human (lane 1) and mouse (lane 2) brains. Among
the control mice, PrPres was not detected in the brain and
spleen of any animal or in neoplastic tissues of the single
affected animal (Table).
Conclusions
Using immunohistochemical (IHC) tests, Hilton and
colleagues (1) showed widespread PrPres accumulation in
the lymphoreticular system of 54 vCJD patients but not in
56 patients with familial or sporadic CJD. In contrast,
when sodium phosphotungstate concentration for PrPres
was used to increase the sensitivity of the WB, PrPres was
detected in spleens of ≈30% of patients with sporadic CJD
(11). A similar high-sensitivity detection method was used
to screen 2,000 tonsils from the general population in a
recently reported prospective study, with a negative result
(12). The same method did not show PrPres in the tonsils
and 1 lymph node of an 83-year-old person who died from
nonneurologic disease but who, 5 years before death,
received a blood transfusion from a person in whom vCJD
later developed (3, R. Will, pers. comm.). However, anoth-
er cervical lymph node of this person tested positive for
PrPres by IHC test, although the appendix tested negative.
This observation suggests that large retrospective and
prospective studies based on screening of appendixes and
tonsils with WB may not detect persons who have PrPres in
their lymph nodes. Estimates of prevalence of persons
infected with the vCJD agent in the UK population may
have been biased as a consequence of specimen selection
from mostly younger participants. Aretrospective study of
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Figure. Immunoblot for protease-resistant prion protein (PrPres)
from tissues of SJL/OlaHsd mouse infected with human variant
Creutzfeld-Jakob disease (vCJD). Lanes 1–5 show representative
pattern of extracted PrPres after digestion with proteinase K (100
µg/mL). Lane 1, brain tissue of vCJD patient (World Health
Organization reference sample). Lanes 2–5, samples from vCJD
mouse in which spontaneous lymphoreticular system tumors
developed: lane 2, brain; lane 3, spleen with nodular tumors; lane
4, tissue from neoplastic lymph nodes; lane 5, neoplastic thymus.
The amount of original tissue used for PrPres extraction is shown
on the top. Samples were denatured by boiling for 10 min in
Laemmli buffer containing 2% β-mercaptoethanol, resolved on
NuPAGE 12% Bis-Tris gel (Invitrogen Life Technologies, Carlsbad,
CA, USA), transferred to nitrocellulose membrane, and probed
with anti-PrP monoclonal antibody 6D11 (dilution 1:5,000). Major
glycoforms of PrPres are present as 3 bands corresponding to
diglycosylated, monoglycosylated, and unglycosylated molecules.>8,000 specimens of appendixes and tonsils included
≈70% from persons 20–29 years of age (2), and in a
prospective study, approximately half the tonsillectomy
samples came from children <9 years of age (12). 
Our observation of the widespread presence of PrPres in
neoplastic lymph nodes of mice infected with the vCJD
agent, and its absence in an uninfected mouse, provides
experimental evidence that such tissues could be a valuable
source for screening for vCJD in humans. The finding of
unusually high amounts of PrPres in neoplastic lymphoretic-
ular tissues of vCJD mice, in a range comparable to that of
the human and mouse brain, suggests that rapidly growing
lymphoreticular tumors accumulate PrPres at a high rate.
Therefore, PrPres might be detected in neoplastic lym-
phoreticular tissues of persons with vCJD. This finding is
of particular importance because a recent UK study of sam-
ples collected before 1986, the years preceding the vCJD
epidemic, found no PrPres in lymph nodes from 58 patients
with reactive conditions and 21 patients with lymphomas
and carcinomas (1), which indicates that PrPres does not
spontaneously accumulate in tumors of uninfected persons.
Whether PrPres starts to accumulate in lymph nodes before
it appears in spleens, appendixes, or tonsils of persons
infected with the vCJD agent is not known. In vCJD mice,
we observed PrPres in the brain and neoplastic spleens and
lymph nodes during at least half of the incubation period
(199 days) when compared to mice with the longest sur-
vival time (>380 days). On the basis of our findings, we
propose that screening of lymph node tissues from persons
with reactive and neoplastic conditions and patients with
various cancers with metastases in lymphoreticular organs
could provide additional information, especially regarding
older persons, on the prevalence of vCJD in the United
Kingdom and other European countries.
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